Additionally, adjuvant-free approaches are emerging, as demonstrated by Herbin et al., who showed that continuous low-dose delivery of ApoB peptide mixtures via subcutaneous minipumps effectively reduced atherosclerosis by inducing Treg responses [188]. This evidence concerns the gene APOB and atherosclerosis.